<p>精准科学公司（NASDAQ:EXAS - 获取免费报告）周二股价下跌 4.3%。该公司股价最低曾达到 55.92 美元，最后交易价为 56.01 美元。在交易过程中，约有 652,498 股易手，较日均交易量 1,890,406 股下降了 65%。该股票此前收盘价为 58.51 美元。</p>
<p>获取 <strong>精准科学</strong> 的提醒：</p>
<h2>分析师评级上调与下调</h2>
<ul>
<li>Myriad Genetics 因遗传性癌症检测股价飙升</li>
</ul>
<p>几位分析师最近对该股票发表了看法。Benchmark 在周一的报告中重申了对精准科学的 “买入” 评级，并给出了 65.00 美元的目标价。Craig Hallum 在 11 月 6 日的研究报告中将精准科学的目标价从 82.00 美元下调至 65.00 美元，并对该股票给予 “买入” 评级。BTIG Research 在 11 月 26 日的研究报告中将精准科学的目标价从 65.00 美元上调至 75.00 美元，并给予该股票 “买入” 评级。TD Cowen 在 11 月 26 日的报告中将精准科学的目标价从 82.00 美元上调至 86.00 美元，并给予公司 “买入” 评级。最后，美国银行在 12 月 13 日的研究报告中将精准科学的目标价从 75.00 美元下调至 72.00 美元，并对该股票给予 “买入” 评级。一位股票研究分析师对该股票给予了持有评级，十七位分析师给予了该公司股票 “买入” 评级。根据 MarketBeat.com 的数据，精准科学目前的共识评级为 “适度买入”，平均目标价为 72.94 美元。</p>
<p><strong>获取我们最新的精准科学股票报告</strong></p>
<h2>精准科学股票表现</h2>
<ul>
<li>国会议员购买的 3 只热门股票：跟随资金流动</li>
</ul>
<p>该公司的速动比率为 1.93，流动比率为 2.12，债务与股本比率为 0.72。该公司的市值为 93.4 亿美元，市盈率为-43.11，贝塔值为 1.24。该公司的 50 日简单移动平均线为 57.20 美元，200 日简单移动平均线为 59.03 美元。</p>
<p>精准科学（NASDAQ:EXAS - 获取免费报告）最近于 11 月 5 日发布了季度财报。这家医疗研究公司报告季度每股收益为（0.21 美元），低于市场共识预期的（0.20 美元）0.01 美元。精准科学的净利润率为-7.95%，股本回报率为-6.17%。该公司在本季度的收入为 7.0866 亿美元，而分析师预期为 7.1680 亿美元。该公司的季度收入同比增长 12.8%。平均而言，卖方分析师预测精准科学公司本财年的每股收益将为-1.1 美元。</p>
<h2>精准科学的内部交易</h2>
<ul>
<li>现在是购买这 3 家提高收入指引的医疗公司吗？</li>
</ul>
<p>在相关消息中，首席执行官 Kevin T. Conroy 于 11 月 13 日星期三购买了 19,500 股精准科学的股票。该股票的平均购买成本为每股 51.35 美元，总价值为 1,001,325.00 美元。购买后，首席执行官现在直接持有公司 1,074,191 股股票，价值约为 55,159,707.85 美元。此次交易使其持股增加了 1.85%。该购买在提交给证券交易委员会的文件中披露，该文件可通过 SEC 网站访问。内部人士持有公司股票的 1.36%。</p>
<h2>机构资金流入与流出</h2>
<p>机构投资者最近调整了对该股票的持有。Groupama Asset Managment 在第三季度收购了精准科学的新股份，价值 821,000 美元。Sculptor Capital LP 在第二季度购买了精准科学的新头寸，价值 32,819,000 美元。Samlyn Capital LLC 在第二季度收购了精准科学的新股份，价值 30,426,000 美元。Armistice Capital LLC 在第二季度将其在精准科学的持股增加了 91.6%。Armistice Capital LLC 现在拥有 1,400,086 股该医疗研究公司的股票，价值 59,154,000 美元，此前在上个季度又收购了 669,438 股。最后，ArrowMark Colorado Holdings LLC 在第三季度收购了精准科学的新头寸，价值约 28,608,000 美元。机构投资者和对冲基金持有公司 88.82% 的股票。</p>
<h2>精准科学公司简介</h2>
<p>（获取免费报告）</p>
<p>精准科学公司在美国和国际上提供癌症筛查和诊断测试产品。该公司提供 Cologuard，一种非侵入性的基于粪便的 DNA 筛查测试，用于检测与结直肠癌和癌前病变相关的 DNA 和血红蛋白生物标志物。它还提供 Oncotype DX 乳腺复发评分测试；Oncotype DX 乳腺 DCIS 评分测试；Oncotype DX 结肠复发评分测试；OncoExTra 测试，用于对晚期、转移性、耐药、复发或复发癌症患者进行肿瘤分析；以及 Covid-19 检测服务。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票超过精准科学</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>Cerence AI：一锤子买卖还是与 NVIDIA 协议后的长期赢家？</li>
<li>10 美元以下的最佳股票</li>
<li>UnitedHealth Group 再次回归健康机会</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>美光科技：乘着 AI 浪潮实现长期增长</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在精准科学吗？</h2>
<p>在考虑精准科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而精密科学并不在名单上。</p>
<p>虽然精密科学目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

精密科学

<p>精密科学（NASDAQ:EXAS）股价下跌 4.3%，至 56.01 美元，交易量较平均水平下降 65%。分析师对该公司的前景总体持积极态度，给予 “适度买入” 的共识评级，平均目标价为 72.94 美元。最近的季度财报显示收入为 7.0866 亿美元，未达到预期。首席执行官 Kevin T. Conroy 购买了 19,500 股，增加了他的持股比例。机构投资者持有 88.82% 的股份，表明该公司在癌症筛查和诊断测试领域受到强烈的机构关注</p>

<p>Shares of Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) were down 4.3% on Tuesday . The company traded as low as $55.92 and last traded at $56.01. Approximately 652,498 shares changed hands during trading, a decline of 65% from the average daily volume of 1,890,406 shares. The stock had previously closed at $58.51.</p>
<div class="lb-trans"><p>精准科学公司（NASDAQ:EXAS - 获取免费报告）周二股价下跌 4.3%。该公司股价最低曾达到 55.92 美元，最后交易价为 56.01 美元。在交易过程中，约有 652,498 股易手，较日均交易量 1,890,406 股下降了 65%。该股票此前收盘价为 58.51 美元。</p>
</div><p>Get <strong>Exact Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>精准科学</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 因遗传性癌症检测股价飙升</li>
</ul>
</div><p>Several analysts recently weighed in on the stock. Benchmark reaffirmed a &#34;buy&#34; rating and issued a $65.00 target price on shares of Exact Sciences in a report on Monday. Craig Hallum dropped their price objective on shares of Exact Sciences from $82.00 to $65.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, November 6th. BTIG Research lifted their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, November 26th. TD Cowen increased their target price on Exact Sciences from $82.00 to $86.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 26th. Finally, Bank of America cut their price target on Exact Sciences from $75.00 to $72.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, Exact Sciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $72.94.</p>
<div class="lb-trans"><p>几位分析师最近对该股票发表了看法。Benchmark 在周一的报告中重申了对精准科学的 “买入” 评级，并给出了 65.00 美元的目标价。Craig Hallum 在 11 月 6 日的研究报告中将精准科学的目标价从 82.00 美元下调至 65.00 美元，并对该股票给予 “买入” 评级。BTIG Research 在 11 月 26 日的研究报告中将精准科学的目标价从 65.00 美元上调至 75.00 美元，并给予该股票 “买入” 评级。TD Cowen 在 11 月 26 日的报告中将精准科学的目标价从 82.00 美元上调至 86.00 美元，并给予公司 “买入” 评级。最后，美国银行在 12 月 13 日的研究报告中将精准科学的目标价从 75.00 美元下调至 72.00 美元，并对该股票给予 “买入” 评级。一位股票研究分析师对该股票给予了持有评级，十七位分析师给予了该公司股票 “买入” 评级。根据 MarketBeat.com 的数据，精准科学目前的共识评级为 “适度买入”，平均目标价为 72.94 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Exact Sciences</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的精准科学股票报告</strong></p>
</div><h2>Exact Sciences Stock Performance</h2>
<div class="lb-trans"><h2>精准科学股票表现</h2>
</div><ul>
<li>3 Hot Stocks Bought by Members of Congress: Follow the Money</li>
</ul>
<div class="lb-trans"><ul>
<li>国会议员购买的 3 只热门股票：跟随资金流动</li>
</ul>
</div><p>The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The company has a market cap of $9.34 billion, a price-to-earnings ratio of -43.11 and a beta of 1.24. The firm has a 50-day simple moving average of $57.20 and a 200 day simple moving average of $59.03.</p>
<div class="lb-trans"><p>该公司的速动比率为 1.93，流动比率为 2.12，债务与股本比率为 0.72。该公司的市值为 93.4 亿美元，市盈率为-43.11，贝塔值为 1.24。该公司的 50 日简单移动平均线为 57.20 美元，200 日简单移动平均线为 59.03 美元。</p>
</div><p>Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The business had revenue of $708.66 million during the quarter, compared to analysts' expectations of $716.80 million. The company's revenue for the quarter was up 12.8% on a year-over-year basis. On average, sell-side analysts predict that Exact Sciences Co. will post -1.1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>精准科学（NASDAQ:EXAS - 获取免费报告）最近于 11 月 5 日发布了季度财报。这家医疗研究公司报告季度每股收益为（0.21 美元），低于市场共识预期的（0.20 美元）0.01 美元。精准科学的净利润率为-7.95%，股本回报率为-6.17%。该公司在本季度的收入为 7.0866 亿美元，而分析师预期为 7.1680 亿美元。该公司的季度收入同比增长 12.8%。平均而言，卖方分析师预测精准科学公司本财年的每股收益将为-1.1 美元。</p>
</div><h2>Insider Transactions at Exact Sciences</h2>
<div class="lb-trans"><h2>精准科学的内部交易</h2>
</div><ul>
<li>Time to buy these 3 healthcare companies that raised revenue guidance?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是购买这 3 家提高收入指引的医疗公司吗？</li>
</ul>
</div><p>In related news, CEO Kevin T. Conroy acquired 19,500 shares of Exact Sciences stock in a transaction on Wednesday, November 13th. The stock was purchased at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the purchase, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders own 1.36% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Kevin T. Conroy 于 11 月 13 日星期三购买了 19,500 股精准科学的股票。该股票的平均购买成本为每股 51.35 美元，总价值为 1,001,325.00 美元。购买后，首席执行官现在直接持有公司 1,074,191 股股票，价值约为 55,159,707.85 美元。此次交易使其持股增加了 1.85%。该购买在提交给证券交易委员会的文件中披露，该文件可通过 SEC 网站访问。内部人士持有公司股票的 1.36%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Groupama Asset Managment acquired a new stake in shares of Exact Sciences during the third quarter worth $821,000. Sculptor Capital LP purchased a new position in Exact Sciences during the 2nd quarter worth $32,819,000. Samlyn Capital LLC acquired a new stake in shares of Exact Sciences in the 2nd quarter worth $30,426,000. Armistice Capital LLC boosted its holdings in shares of Exact Sciences by 91.6% in the second quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company's stock valued at $59,154,000 after acquiring an additional 669,438 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC acquired a new position in shares of Exact Sciences during the third quarter worth about $28,608,000. Institutional investors and hedge funds own 88.82% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该股票的持有。Groupama Asset Managment 在第三季度收购了精准科学的新股份，价值 821,000 美元。Sculptor Capital LP 在第二季度购买了精准科学的新头寸，价值 32,819,000 美元。Samlyn Capital LLC 在第二季度收购了精准科学的新股份，价值 30,426,000 美元。Armistice Capital LLC 在第二季度将其在精准科学的持股增加了 91.6%。Armistice Capital LLC 现在拥有 1,400,086 股该医疗研究公司的股票，价值 59,154,000 美元，此前在上个季度又收购了 669,438 股。最后，ArrowMark Colorado Holdings LLC 在第三季度收购了精准科学的新头寸，价值约 28,608,000 美元。机构投资者和对冲基金持有公司 88.82% 的股票。</p>
</div><h2>Exact Sciences Company Profile</h2>
<div class="lb-trans"><h2>精准科学公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.</p>
<div class="lb-trans"><p>精准科学公司在美国和国际上提供癌症筛查和诊断测试产品。该公司提供 Cologuard，一种非侵入性的基于粪便的 DNA 筛查测试，用于检测与结直肠癌和癌前病变相关的 DNA 和血红蛋白生物标志物。它还提供 Oncotype DX 乳腺复发评分测试；Oncotype DX 乳腺 DCIS 评分测试；Oncotype DX 结肠复发评分测试；OncoExTra 测试，用于对晚期、转移性、耐药、复发或复发癌症患者进行肿瘤分析；以及 Covid-19 检测服务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Exact Sciences</li>
<li>Canada Bond Market Holiday: How to Invest and Trade</li>
<li>Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?</li>
<li>Best Stocks Under $10.00</li>
<li>UnitedHealth Group Pulls Back Into Another Healthy Opportunity</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Micron Technology: Riding the AI Wave to Long-Term Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过精准科学</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>Cerence AI：一锤子买卖还是与 NVIDIA 协议后的长期赢家？</li>
<li>10 美元以下的最佳股票</li>
<li>UnitedHealth Group 再次回归健康机会</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>美光科技：乘着 AI 浪潮实现长期增长</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Exact Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在精准科学吗？</h2>
</div><p>Before you consider Exact Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑精准科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而精密科学并不在名单上。</p>
</div><p>While Exact Sciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然精密科学目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

精密科学（NASDAQ:EXAS）股价下跌 4.3% - 接下来会发生什么？